US 11,944,663 B2
Method for treating angiogenic eye disorders using VEGF antagonists
Zunhong Ke, Chengdu (CN)
Assigned to Chengdu Kanghong Biotechnologies Co. Ltd., (CN)
Filed by Chengdu Kanghong Biotechnologies Co. Ltd., Chengdu (CN)
Filed on Jun. 18, 2021, as Appl. No. 17/351,723.
Claims priority of provisional application 63/040,850, filed on Jun. 18, 2020.
Prior Publication US 2021/0393738 A1, Dec. 23, 2021
Int. Cl. A61K 38/17 (2006.01); A61K 47/12 (2006.01); A61K 47/18 (2017.01); A61K 47/26 (2006.01); A61K 47/68 (2017.01); A61P 27/02 (2006.01)
CPC A61K 38/179 (2013.01) [A61K 47/12 (2013.01); A61K 47/183 (2013.01); A61K 47/26 (2013.01); A61K 47/6811 (2017.08); A61P 27/02 (2018.01)] 17 Claims
 
1. A method for treating an angiogenic eye disorder in a human patient, said method comprising a first treatment phase comprising sequentially administering to the patient a VEGF antagonist at 4-week intervals on Day 1, Week 4 and Week 8; wherein the VEGF antagonist comprises amino acid sequence of SEQ ID NO:1, further comprising a second treatment phase, the second treatment phase comprises administering to the patient the VEGF antagonist at 8-week intervals or 12-week intervals until about 36 weeks from the initiation of the treatment, and comprising a third treatment phase, wherein the third treatment phase starts from week 40 and comprises administering the VEGF antagonist on a PRN basis; wherein upon treatment the patient has a decrease in retinal thickness by at least about 80 μm.